Tumor ablation is referred to as a minimally invasive technique that is commonly used in the treatment of tumors of the liver, kidney, bone, and lung among others. It can be used as a first-line treatment or in cases of failed chemotherapy or radiotherapy or for any non-surgical candidates. Ablation systems in general comprise of a generator and a needlelike device that delivers the energy directly to the targeted tissue to cause acute cellular necrosis. The tumor ablation market is witnessing growth due to factors such as growing geriatric population and increasing cancer population. Moreover, technological advancement in ablation devices will further fuel the growth of tumor ablation over the forecast period. However, high cost of tumor ablation treatment is likely to restrain the market to a certain extent.
Market Industry Reports (MIR) has published a new report titled "Tumor Ablation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global tumor Ablation is estimated to be over US$ 545.3 Mn in 2018. It is anticipated to grow at 11.1% CAGR from 2019 to 2030.
Major Key Players of the Tumor Ablation Market are:
Medtronic, Integra LifeSciences Corporation, AngioDynamics, Boston Scientific Corporation, NeuWave Medical, (Johnson & Johnson Services), Galil Medical Inc. (BTG International Ltd), Misonix, HealthTronics, Inc., Sonacare Medical, MERMAID MEDICAL A/S among others.
Read More @ http://www.sbwire.com/press-releases/tumor-ablation-market-to-witness-an-outstanding-growth-during-2019-2030-medtronic-integra-lifesciences-angiodynamics-1280363.htm
According to World Health Organization, around 13% of the populace worldwide is aged 65 and above. The incidence of cancer is increasing with ageing. Around 60% of all cancer cases are diagnosed in patients aged 65 and above. Age related changes in the body are associated with an increased susceptibility to toxicity during chemotherapy and also, surgery is not offered to older patients mostly due to increased risk of surgical mortality. For the aged patients, who are not qualified for surgery and for whom chemotherapy is not a suitable option, there are technologies such as Radiofrequency Ablation (RFA), Microwave ablation (MWA) and Cryoablation to treat their cancer. This is expected to propel the growth of the tumor ablation market.
Read More @ http://www.sbwire.com/press-releases/tumor-ablation-market-to-witness-an-outstanding-growth-during-2019-2030-medtronic-integra-lifesciences-angiodynamics-1280363.htm
Market Industry Reports (MIR) has published a new report titled "Tumor Ablation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global tumor Ablation is estimated to be over US$ 545.3 Mn in 2018. It is anticipated to grow at 11.1% CAGR from 2019 to 2030.
Major Key Players of the Tumor Ablation Market are:
Medtronic, Integra LifeSciences Corporation, AngioDynamics, Boston Scientific Corporation, NeuWave Medical, (Johnson & Johnson Services), Galil Medical Inc. (BTG International Ltd), Misonix, HealthTronics, Inc., Sonacare Medical, MERMAID MEDICAL A/S among others.
Read More @ http://www.sbwire.com/press-releases/tumor-ablation-market-to-witness-an-outstanding-growth-during-2019-2030-medtronic-integra-lifesciences-angiodynamics-1280363.htm
The significant growth of the market can be attributed to growing number of geriatric population followed by increasing number of cancer patients. Moreover, technological advancements in ablation devices in emerging countries, is anticipated to boost the growth of the tumor ablation market over the forecast period. However, high cost of tumor ablation treatment is likely to restrain the market to a certain extent.
According to World Health Organization, around 13% of the populace worldwide is aged 65 and above. The incidence of cancer is increasing with ageing. Around 60% of all cancer cases are diagnosed in patients aged 65 and above. Age related changes in the body are associated with an increased susceptibility to toxicity during chemotherapy and also, surgery is not offered to older patients mostly due to increased risk of surgical mortality. For the aged patients, who are not qualified for surgery and for whom chemotherapy is not a suitable option, there are technologies such as Radiofrequency Ablation (RFA), Microwave ablation (MWA) and Cryoablation to treat their cancer. This is expected to propel the growth of the tumor ablation market.
No comments:
Post a Comment